JRCT ID: jRCTs042220078
Registered date:20/10/2022
MEG dementia study
Basic Information
Recruitment status | Pending |
---|---|
Health condition(s) or Problem(s) studied | cognitively unimpaired, mild cognitive impairment/dementia due to Alzheime's disease |
Date of first enrollment | 20/10/2022 |
Target sample size | 42 |
Countries of recruitment | |
Study type | Observational |
Intervention(s) | Magnetoencephalography examination |
Outcome(s)
Primary Outcome | Primary outcomes were (i) the safety and tolerability of MEG examination, (ii) the maximum power in the left ventral Brodmann area 9/46 in the dorsolateral prefrontal cortex (DLPFC) and the power-ratio of the inferior parietal lobule (IPL)/ medial ventral occipital cortex (MVOcC) in the dorsal stream during the optic flow task. |
---|---|
Secondary Outcome | Secondary outcomes were [i] brain activity at the dorsal stream and DLPFC during the optic flow task, and [ii] brain activity of mean frequency and alpha peak frequency at resting with eye closed mean frequency and alpha peak frequency |
Key inclusion & exclusion criteria
Age minimum | >= 65age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | Primary registration [I] A full medical checkup examinee [II] Patients with MCI due to AD at Kanazawa university hospital [III] Patients with AD dementia at Kanazawa university hospital Secondary registration [IV] Cognitively unimpaired [CU] group [V] AD-MCI group [VI] AD group [I] A full medical checkup examinee [i] Age greater than 65 years [ii] Individuals who have a full medical checkup at Kanazawa Advanced Medical Center [iii] Written informed consent was obtained from the participant [II] Patients with MCI due to AD at Kanazawa university hospital [i] Age greater than 65 years [ii] Diagnosis of probable mild cognitive impairment [MCI] due to Alzheimer's disease [AD] with high evidence of the pathophysiological process, according to the criteria of the National Institute on Aging Alzheimer's Association Workgroup [NIAAA]. [iii] Written informed consent ans assent were obtained from the legal representative and the patient, respectively. [III] Patients with AD dementia at Kanazawa university hospital [i] Age greater than 65 years [ii] Diagnosis of probable AD dementia with high evidence of the pathophysiological process, according to the criteria of the National Institute on Aging Alzheimer's Association Workgroup [NIAAA]. [iii] Written informed consent ans assent were obtained from the legal representative and the patient, respectively. [IV] Cognitively unimpaired [CU] group [i] A full medical checkup examinee at the primary registration [ii] Diagnosed as cognitive unimpaired by the investigators [V] AD-MCI group [i] Out patients of Kanazawa university hospital at the primary registration [ii] Diagnosed as MCI due to AD by the investigators [VI] AD group [i] Out patients of Kanazawa university hospital at the primary registration [ii] Diagnosed as AD dementia by the investigators |
Exclude criteria | Primary registration [I] A full medical checkup examinee [II] Patients with MCI due to AD at Kanazawa university hospital [III] Patients with AD dementia at Kanazawa university hospital Secondary registration [IV] Cognitively unimpaired [CU] group [V] AD-MCI group [VI] AD group [I] A full medical checkup examinee [i] Individuals who is unable to take an MRI scan, such as a claustrophobia or having any kind of metal in the body [ii] Assessed as inappropriate to join the clinical trial by the investigator [II] Patients with MCI due to AD at Kanazawa university hospital [i] Individuals who is unable to take an MRI scan, such as a claustrophobia or having any kind of metal in the body [ii] Assessed as inappropriate to join the clinical trial by the investigator [III] Patients with AD dementia at Kanazawa university hospital [i] Individuals who is unable to take an MRI scan, such as a claustrophobia or having any kind of metal in the body [ii] Assessed as inappropriate to join the clinical trial by the investigator [IV] Cognitively unimpaired [CU] group [i] Assessed as inappropriate by the investigator [V] AD-MCI group [i] Individuals who have a full medical checkup at Kanazawa Advanced Medical Center [ii] Assessed as inappropriate by the investigator [VI] AD group [i] Individuals who have a full medical checkup at Kanazawa Advanced Medical Center [ii] Assessed as inappropriate by the investigator |
Related Information
Primary Sponsor | Ono Kenjiro |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Moeko Shinohara |
Address | 13-1, Takara-machi, Kanazawa, Ishikawa Ishikawa Japan 920-8640 |
Telephone | +81-76-265-2292 |
megdock@med.kanazawa-u.ac.jp | |
Affiliation | Kanazawa university hospital |
Scientific contact | |
Name | Kenjiro Ono |
Address | 13-1, Takaramachi, Kanazawa, Ishikawa Ishikawa Japan 920-8640 |
Telephone | +81-76-265-2000 |
onoken@med.kanazawa-u.ac.jp | |
Affiliation | Kanazawa university hospital |